title: [Elevated C reactive protein rate in 23 black African patients with systemic lupus erythematosus and without opportunistic infectious disease].
abstract: BACKGROUND
  CRP rarely increases during systemic lupus exacerbations.
  
  
  METHODS
  This retrospective study of patients with systemic lupus diagnosed according to ACR criteria examined all patients with no intercurrent infectious disease and responding to corticosteroid treatment and compared the patients with normal and with significantly elevated (> or = 30 mg/l) CRP.
  
  
  RESULTS
  23 black patients (22 women, 1 man) were selected and classified in two groups: group I with CRP > 30 mg/l (n = 12) and the controls, group II, with normal CRP (n =11). In group I, mean CRP was 279 mg/l. Four patients had isolated pericarditis, and one pericarditis associated with pleurisy. Nine patients had no cardiovascular risk factors or abnormal liver function enzymes. Antinuclear antibodies were specific for anti-DNA (n= 8), anti-Sm (n = 2), anti-RNP (n = 1), and anti-SSA (n = 1). In group II, seven patients had pericarditis, and nine had no cardiovascular risk factors or liver function results. Antinuclear antibodies were specific for anti-DNA (n = 9), anti-Sm (n = 1) and unknown (n = 1).
  
  
  CONCLUSIONS
  The paucity of data about black Africans in the literature makes it difficult to interpret these results in terms of their specificity for this population or as a typical profile of elevated CRP without infectious disease.
  
  
  CONCLUSIONS
  In absence of a specific profile for patients with elevated CRP without intercurrent infectious disease, we consider the possibility of a subgroup of the black population that may be particularly vulnerable and express CRP more easily.
authors.affiliation: Service de médecine A, Centre hospitalier de Libreville, BP 2228 Libreville, Gabon. ibabajose@yahoo.fr
authors.forename: J
authors.initials: J
authors.lastname: Iba-Ba
authors.forename: B
authors.initials: B
authors.lastname: Biteghe
authors.forename: L
authors.initials: L
authors.lastname: Missounga
authors.forename: R Bignoumba
authors.initials: RB
authors.lastname: Ibouili
authors.forename: J B
authors.initials: JB
authors.lastname: Mipinda
authors.forename: S
authors.initials: S
authors.lastname: Coniquet
authors.forename: J B Moussavou
authors.initials: JB
authors.lastname: Kombila
authors.forename: J B
authors.initials: JB
authors.lastname: Boguikouma
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D017954:Africa South of the Sahara; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis*; D004452:Echocardiography; D005260:Female; D005681:Gabon; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood* / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010493:Pericarditis / Q000150:complications; D010998:Pleurisy / Q000150:complications; D012189:Retrospective Studies
chemical_list: D000305:Adrenal Cortex Hormones; D000974:Antibodies, Antinuclear; D002097:C-Reactive Protein